AbCellera Biologics Q2 EPS $(0.11) Beats $(0.13) Estimate, Sales $10.06M Miss $12.37M Estimate
Portfolio Pulse from saritha@benzinga.com
AbCellera Biologics reported Q2 losses of $(0.11) per share, beating the analyst consensus estimate of $(0.13) by 15.38%. However, the company's quarterly sales of $10.06 million missed the analyst consensus estimate of $12.37 million by 18.71%. This represents a 78.10% decrease in sales compared to the same period last year.
August 04, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbCellera Biologics' Q2 earnings beat estimates but sales missed, indicating mixed financial performance.
AbCellera Biologics reported better than expected earnings per share, which is a positive signal for investors. However, the company's sales missed estimates, which could be a concern. The mixed results may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100